33592-56-2Relevant academic research and scientific papers
Ligand-free (: Z)-selective transfer semihydrogenation of alkynes catalyzed by in situ generated oxidizable copper nanoparticles
Grela, Karol,Kusy, Rafa?
supporting information, p. 5494 - 5502 (2021/08/16)
Herein, we present (Z)-selective transfer semihydrogenation of alkynes based on in situ generated CuNPs in the presence of hydrogen donors, such as ammonia-borane and a green protic solvent. This environmentally friendly method is characterized by operational simplicity combined with high stereo- and chemoselectivity and functional group compatibility. Auto-oxidation of CuNPs after the completion of a semihydrogenation reaction results in the formation of a water-soluble ammonia complex, so that the catalyst may be reused several times by simple phase-separation with no need for any special regeneration processes. Formed NH4B(OR)4 can be easily transformed back into ammonia-borane or into boric acid. In addition, a one-pot tandem sequence involving a Suzuki reaction followed by semihydrogenation was presented, which allows minimization of chemical waste production.
Palladium anchored on guanidine-terminated magnetic dendrimer (G3-Gu-Pd): An efficient nano-sized catalyst for phosphorous-free Mizoroki-Heck and copper-free Sonogashira couplings in water
Khalafi-Nezhad, Ali,Moaddeli, Ali,Niknam, Esmaeil
, (2020/07/25)
In this research, a novel type of Fe3O4&at;silica-supported dendrimer capped by guanidine groups for immobilization of palladium was reported. This novel nano-sized catalyst was characterized by FTIR, TGA, XRD, FESEM, EDX, VSM, XPS and HRTEM methods. Enhanced catalytic activity of the prepared catalyst in Mizoroki-Heck and copper-free Sonogashira coupling reactions were evaluated in water as a green solvent. The influence of the various reaction parameters such as catalyst dosage, time and temperature on two mentioned C–C coupling reactions were studied. Results showed that the catalyst could be easily recovered by simple separation by an external magnet and reused for five cycles of recovery without considerable losing of its activity.
Design, synthesis, and biological evaluation of linear 1-(4-, 3- or 2-methylsulfonylphenyl)-2-phenylacetylenes: A novel class of cyclooxygenase-2 inhibitors
Chen, Qiao-Hong,Rao, P. N. Praveen,Knaus, Edward E.
, p. 6425 - 6434 (2007/10/03)
A group of regioisomeric 1-(methylsulfonylphenyl)-2-phenylacetylenes possessing a COX-2 SO2Me pharmacophore at the para-, meta- or ortho-position of the C-1 phenyl ring, in conjunction with a C-2 phenyl or substituted-phenyl ring substituent (3
Pd/C-mediated coupling of aryl halides with terminal alkynes in water
Batchu, Venkateswara Rao,Subramanian, Venkataraman,Parasuraman, Karuppasamy,Swamy, Nalivela Kumara,Kumar, Sanjeev,Pal, Manojit
, p. 9869 - 9877 (2007/10/03)
2-Aminoethanol facilitated the alkynylation of aryl halides (Sonogashira reaction) under palladium/charcoal-copper catalysis in water affording a mild and practical method for the synthesis of arylalkynes. A variety of terminal alkynes were coupled with a
BISARYLCYCLOBUTENE DERIVATES AS CYCLOOXYGENASE INHIBITORS
-
, (2008/06/13)
The invention encompasses the novel compound of formula (I) useful in the treatment of cyclooxygenase-2 mediated diseases. The invention also encompasses certain pharmaceutical compositions for treatment of cyclooxygenase-2 mediated diseases comprising compounds of formula (I).
Bisaryl cyclobutenes derivatives as cyclooxygenase inhibitors
-
, (2008/06/13)
The invention encompasses the novel compound of Formula I useful in the treatment of cyclooxygenase-2 mediated diseases. STR1 The invention also encompasses certain pharmaceutical compositions for treatment of cyclooxygenase-2 mediated diseases comprising
Novel 1,2-diarylcyclobutenes: Selective and orally active COX-2 inhibitors
Friesen, Richard W.,Dube, Daniel,Fortin, Rejean,Frenette, Richard,Prescott, Sylvie,Cromlish, Wanda,Greig, Gillian M.,Kargman, Stacia,Wong, Elizabeth,Chan, Chi Chung,Gordon, Robert,Xu, Li Jing,Riendeau, Denis
, p. 2677 - 2682 (2007/10/03)
A series of novel 2,3-diaryl-2-cyclobuten-1-ones have been synthesized and have been evaluated with respect to their ability to inhibit the isozymes of cyclooxygenase, COX-1 and COX-2. 4,4-Dimethyl-2-phenyl-3-[4-(methylsulfonyl)phenyl]cyclobutenone 22 was found to be highly selective for inhibition of COX-2 and was orally active (ED50 = 2.4 mg/kg) in the rat paw edema model.
